Qi Zhou

Dr. Qi Zhou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
JZJia Zhang
Jia Zhang
QZQian Zhang
Qian Zhang
HGHongqiu Gu
Hongqiu Gu
QZQi Zhou
Qi Zhou
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD
XZXingquan Zhao
Xingquan Zhao
Objective: To compare the effect of different indicators on stress‐induced hyperglycemia for predicting in‐hospital outcomes of acute intracerebral hemorrhage.Methods: Using data from the Chinese Stroke Center Alliance database, which is a national, multicenter, prospective, and consecutive program. Stress‐induced hyperglycemia was described as glycemic gap (GG, defined as fasting blood glucose [FBG] minus estimated average blood glucose) and stress hyperglycemia ratio (SHR, defined as FBG‐to‐estimated average blood glucose ratio [SHR 1] or FBG‐to‐HbA1c ratio [SHR 2]). The primary outcome was in‐hospital mortality, and the second outcome was hematoma expansion.Results: A total of 71,333 patients with acute intracerebral hemorrhage were included. In multivariate analyses, the highest levels of GG (OR 1.68, 95% CI 1.12–2.51), SHR 1 (OR 1.73, 95% CI 1.15–2.60), and SHR 2 (OR 2.07, 95% CI 1.33–3.23) were associated with in‐hospital death (all the p trends 0.05) was related to hematoma expansion. No association between GG or SHR 1 and hematoma expansion was observed. The areas under the ROC curve of GG, SHR 1, and SHR 2 for in‐hospital mortality were 0.8808 (95% CI 0.8603–0.9014), 0.8796 (95% CI 0.8589–0.9002), and 0.8806 (95% CI 0.8600–0.9012). The areas under the ROC curve of SHR 2 for hematoma expansion were 0.7133 (95% CI 0.6964–0.7302).Interpretation: SHR (FBG‐to‐HbA1c ratio) was associated with both in‐hospital death and hematoma expansion in intracerebral hemorrhage, and might serve as an accessory indicator for the in‐hospital prognosis of intracerebral hemorrhage.

31 October 2024 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
CLChangsheng Li
Changsheng Li
YJYingyu Jiang
Yingyu Jiang
HGHongqiu Gu
Hongqiu Gu
MWMeng Wang
Meng Wang
ZCZimo Chen
Zimo Chen
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD
Background and purpose To date, no large cohort study has investigated the effects of intravenous thrombolysis (IVT) in Chinese patients aged over 80 years who had a stroke. This study aimed to assess the trends in the use of alteplase, the clinical characteristics and the outcomes of Chinese patients aged above 80 years who had an acute ischaemic stroke. Methods Data for this analysis were obtained from the China Stroke Center Alliance programme, a nationwide, multicentre, prospective registry encompassing 1751 hospitals across 31 provinces, covering the period from 1 January 2018 to 14 December 2022. The primary outcome was defined as a modified Rankin Scale (mRS) Score of 0–2 at discharge. Secondary outcomes included an mRS Score of 0–1 and independent ambulation on discharge. Safety outcomes assessed were in-hospital mortality and symptomatic intracranial haemorrhage (sICH). Results Out of 30 902 patients over 80 years old who qualified for thrombolysis, 8673 (median age (IQR), 84 (82–87) years) received alteplase treatment. Patients administered alteplase demonstrated improved short-term functional outcomes, such as an mRS Score of 0–2 (adjusted OR (aOR) 1.12, 95% CI, 1.06 to 1.18, p<0.001), an mRS Score of 0–1 (aOR 1.14, 95% CI, 1.08 to 1.19, p<0.001) and independent ambulation at discharge (aOR 1.14, 95% CI, 1.08 to 1.20, p<0.001). Moreover, no significant increase was observed in the risk of in-hospital mortality (aOR 1.12, 95% CI, 0.93 to 1.35; p=0.23). However, the risk of sICH was significantly higher among patients treated with alteplase (aOR 3.22, 95% CI, 2.77 to 3.75; p<0.001). Conclusions IVT with alteplase in elderly patients who had a stroke resulted in improved short-term functional outcomes without elevating the risk of in-hospital mortality. Nonetheless, this population remains at a higher risk of sICH.

3 October 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
YZYanli Zhang
Yanli Zhang
MWMengxing Wang
Mengxing Wang
XCXueli Cai
Xueli Cai
AJAoming Jin
Aoming Jin
JJJing Jing
Jing Jing
YPYuesong Pan
Yuesong Pan

1 January 2025 in Stroke
Verified
Journal Article
Closed access
YZYanli Zhang
Yanli Zhang
XWXuan Wang
Xuan Wang
YGYing Gao
Ying Gao
WCWeiqi Chen
Weiqi Chen
SJS. Claiborne Johnston
S. Claiborne Johnston
YPYuesong Pan
Yuesong Pan
BACKGROUND: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile. METHODS: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022. Patients were stratified into different groups based on the Essen Stroke Risk Score (ESRS) and modified ESRS. The primary efficacy outcome was any new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding within 90 days. RESULTS: Among 6100 patients (3050 each in the clopidogrel-aspirin group and aspirin group), the median age was 65 years (interquartile range, 57–71 years), and 3915 (64.2%) were male. Clopidogrel-aspirin was associated with a reduced risk of new stroke in patients with an ESRS of <3 (hazard ratio [HR], 0.67 [95% CI, 0.52–0.86]), but not in those with an ESRS of ≥3 (HR, 0.92 [95% CI, 0.72–1.18]), compared with aspirin ( P interaction =0.07). Similar results were found in patients stratified by modified ESRS (modified ESRS <6 in male and <5 in female: HR, 0.68 [95% CI, 0.55–0.83]; modified ESRS ≥6 in male and ≥5 in female: HR, 1.14 [95% CI, 0.82–1.59]; P interaction =0.01). The association between antiplatelet therapy and the moderate-to-severe bleeding did not differ across risk profile subgroups (ESRS of <3: HR, 1.35 [95% CI, 0.54–3.35]; ESRS of ≥3: HR, 3.21 [95% CI, 1.18–8.78]; P interaction =0.21; modified ESRS of <6 in male and <5 in female: HR, 1.96 [95% CI, 0.88–4.36]; modified ESRS of ≥6 in male and ≥5 in female: HR, 2.27 [95% CI, 0.70–7.39]; P interaction =0.85). CONCLUSIONS: This post hoc analysis of the INSPIRES trial showed that patients with a low level of risk profile assessed by ESRS received greater benefit from clopidogrel-aspirin initiated within 72 hours after symptom onset than aspirin alone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03635749.

11 February 2025 in Annals of Neurology
Verified
Journal Article
Closed access
QZQi Zhou
Qi Zhou
YGYing Gao
Ying Gao
WCWeiqi Chen
Weiqi Chen
SJS. Claiborne Johnston
S. Claiborne Johnston
PAPierre Amarenco
Pierre Amarenco
YPYuesong Pan
Yuesong Pan

27 December 2018 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
QZQi Zhou
Qi Zhou
YZYanli Zhang
Yanli Zhang
JZJianhua Zhou
Jianhua Zhou
XYXiangrong Yang
Xiangrong Yang
YHYuqiang Huang
Yuqiang Huang
CMChunling Ma
Chunling Ma
Detection results of free thyroxine (FT4), thyroid stimulating hormone (TSH) and thyroid peroxidase antibody (TPOAb) in pregnant women in Linyi region were investigated. A total of 22,235 healthy pregnant women admitted to Women and Children's Health Care Hospital of Linyi from October 2016 to October 2017 were selected and divided into the first-trimester, second-trimester and third-trimester pregnancy groups. Non-pregnant women in the same period were selected as the control group. Roche E601 electrochemiluminescence apparatus was applied to detect FT4, TSH and TPOAb, and statistical analysis was then carried out for the detected data. The positive rate in the third trimester of pregnancy was obviously higher than those in the first and second trimesters of pregnancy (P<0.05). With the prolongation of pregnancy, the reference interval of FT4 was gradually decreased, among which the intervals in the second and third trimesters of pregnancy were significantly lower than those in the non-pregnancy (P<0.05). With the prolongation of pregnancy, the interval in the first trimester of pregnancy was markedly smaller than that in the non-pregnancy group. With the increase of age, the levels of FT4 and TSH tended to be reduced, but the TSH level was increased to a certain degree in patients aged over 40 years. There were differences in the FT4 and TSH reference intervals during pregnancy in comparison among different regions and different detection methods. Region-specific reference intervals need to be established for different trimesters of pregnancy and different detection methods, which is conducive to accurate clinical judgment of thyroid function during pregnancy. TPOAb monitoring needs to be strengthened in the third trimester of pregnancy, and attention should be paid to the changes in thyroid function in pregnant women aged over 40 years.